Carnot Laboratories is advancing Bofanglutide (GZR18) through a Phase 3 clinical trial (BALANCE-OBS) aimed at evaluating its efficacy and safety compared to Semaglutide in Latin American adults with overweight or obesity. The trial's focus on metabolic parameters, cardiovascular risk factors, and quality of life positions Bofanglutide as a potential competitor in the growing obesity treatment market. Given the increasing prevalence of obesity and related comorbidities, successful outcomes could lead to significant market penetration. However, the competitive landscape includes established products like Semaglutide, which has demonstrated efficacy and safety. Diligence is warranted regarding regulatory pathways and potential market access challenges in the Latin American region.